New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 14, 2012
12:35 EDTPEG, RLI, RL, MCHP, ABC, AET, EXC, ALTR, UNHCongress Asset's Peter Andersen searches for dividend growth, Barron's reports
Peter Andersen, a portfolio manager at Congress Asset Management in Boston, has come up with a screen that shows stocks where the dividend yield could grow because the firms have shown a penchant to increase the dividend and the payout ratio is low. Those with high potential to support growing dividends: UnitedHealth Group (UNH), Aetna (AET), Ralph Lauren (RL), Altera (ALTR), AmerisourceBergen (ABC). Those with low potential: RLI (RLI), Exelon (EXC), Microchip Tech (MCHP) and Public Service Enterprise (PEG). Reference Link
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
November 19, 2015
09:16 EDTUNHUnitedHealth falls on FY15 guidance
Subscribe for More Information
07:46 EDTUNH, AETOptions expected to be active; UNH AET ANTM CI WCG HUM HNT CNC
Subscribe for More Information
06:40 EDTUNHUnitedHealth volatility flat into lowering FY15 guidance
Subscribe for More Information
06:11 EDTUNHUnitedHealth to host conference call
Subscribe for More Information
05:59 EDTUNHUnitedHealth cuts FY15 to $6.00 from $6.25-$6.35
Subscribe for More Information
05:57 EDTUNHUnitedHealth sees FY16 EPS $7.10-$7.30, consensus $7.28
Subscribe for More Information
November 18, 2015
15:40 EDTUNHCongressman says U.S. may need look at pharmacy competition, dealReporter says
Subscribe for More Information
13:44 EDTALTRBefore the Move: Watch Intel into tomorrow's analyst day
Chipmaker Intel's (INTC) analyst day tomorrow could yield information on numerous company operations, but Jefferies analyst Mark Lipacis cautions investors that the probability for positive surprises appears low given recent spending outlays. BACKGROUND: Intel, one of the largest semiconductor makers in the world, is scheduled to hold an analyst day on Thursday, November 19. Beyond providing forecasts for its various business segments and remarks on the larger computer market, Intel is expected to provide further clarity on several recent stories, including its memory joint venture with Micron (MU), plans to invest heavily in a Chinese production facility and progression towards chips on the 10 nanometer scale. STRONG OUTLOOK, MILD MEETING: Intel's pending acquisition of Altera (ALTR) and its plans to invest as much as $5.5B in a computer memory facility in Dalian, China leave little room for positive surprises at tomorrow's event in regards to 2016 margins, capital expenditures, or shareholder returns, Jefferies analyst Mark Lipacis said in a recent research note. That said, the analyst views Intel's Chinese facility expansion as part of a "brilliant investment strategy that positions Intel as a partner to China" and "keeps the market open" to its microprocessors, perhaps Intel's more famed business segment. Though the two initiatives are certain to push up near-term debt load, Lipacis takes the longer-term view, reminding investors that Intel has shown consistently strong free cash flow over the past decade, leading him to forecast another $13B in 2016. The year may also bring "a number" of other positives for the company, including more data center wins after the Altera tie-up, potentially renewed sales on a cyclical uptick in PC gaming, and even the possibility of an iPhone chip contract, though Lipacis said none of those points look set to be discussed tomorrow. The analyst kept a Buy rating and $38 price target on the shares while reiterating that Thursday's Intel event may have little in store for those expecting eye-grabbing surprises. PRICE ACTION: Shares of Intel have advanced roughly 0.9% to $32.92 Wednesday afternoon. "Before the Move" is The Fly's recurring series of exclusive stories that identify potentially market moving events, along with analyst predictions, ahead of the news.
06:46 EDTABCAmerisourceBergen announces Steven Collis to succeed Richard Gozon as Chairman
AmerisourceBergen announced that, following Richard Gozon's retirement as Chairman of the Board at the annual meeting of stockholders in March 2016, Steven Collis, President and CEO, will succeed Gozon as Chairman of the Board, and Jane Henney, will become the board's Lead Independent Director. The election of Collis and Henney is contingent on their re-election as directors at the annual meeting of stockholders scheduled to be held on March 3, 2016.
November 17, 2015
10:47 EDTMCHPMicrochip management to meet with Jefferies
Subscribe for More Information
10:00 EDTEXCOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Antero Resources (AR) initiated with a Buy at Goldman... Applied Micro Circuits (AMCC) initiated with a Buy at Drexel Hamilton... Arc Logistics (ARCX) initiated with a Buy at DA Davidson... CNO Financial (CNO) initiated with a Buy at Goldman... Capstone Turbine (CPST) initiated with a Perform at Oppenheimer... Dominion (D) initiated with an Outperform at Scotia Howard Weil... Duke Energy (DUK) initiated with a Sector Perform at Scotia Howard Weil... EQT Corporation (EQT) initiated with a Neutral at Goldman... EverBank (EVER) initiated with a Hold at Sandler O'Neill... Exelon (EXC) initiated with a Sector Perform at Scotia Howard Weil... First Data (FDC) initiated with a Neutral at BTIG... Genworth (GNW) initiated with a Neutral at Goldman... Marinus Pharmaceuticals (MRNS) initiated with a Buy at Jefferies... New Relic (NEWR) initiated with a Buy at Needham... NextEra Energy Partners (NEP) initiated with a Sector Perform at Scotia Howard Weil... NextEra Energy (NEE) initiated with an Outperform at Scotia Howard Weil... PG&E (PCG) initiated with a Neutral at Citi... Reinsurance Group (RGA) initiated with a Sell at Goldman... The Advisory Board (ABCO) initiated with an Overweight at JPMorgan... Torchmark (TMK) initiated with a Neutral at Goldman... Ubisoft Entertainment (UBSFY) initiated with a Buy at Jefferies.
09:05 EDTUNHOptumRx acquires AxelaCare
Subscribe for More Information
07:47 EDTEXCExelon initiated with a Sector Perform at Scotia Howard Weil
Target $34.
07:27 EDTABCAmerisourceBergen reinstated with an Outperform at Credit Suisse
Subscribe for More Information
November 16, 2015
16:53 EDTALTRPaulson reduced stake in Valeant
Paulson & Co. gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Perrigo (PRGO), CIT Group (CIT), Precision Castparts (PCP), Cameron (CAM), and Altera (ALTR). INCREASED STAKES: Teva (TEVA), Post Holdings (POST), Starwood Hotels (HOT), LivaNova (LIVN), and Synergy Pharmaceuticals (SGYP). DECREASED STAKES: Valeant (VRX), Shire (SHPG), Whiting Petroleum (WLL), Computer Sciences (CSC), and Oasis Petroleum (OAS). LIQUIDATED STAKES: Houghton Mifflin Harcourt (HMHC), Broadcom (BRCM), and Sprint (S).
14:15 EDTPEGPSEG announces approval of $905M program to replace aging gas infrastructure
Subscribe for More Information
10:00 EDTABCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alliant Energy (LNT) upgraded to Outperform from Market Perform at Wells Fargo... AmerisourceBergen (ABC) upgraded to Equal Weight from Underweight at Morgan Stanley... Amphenol (APH) upgraded to Buy from Neutral at Goldman... CA Technologies (CA) upgraded to Neutral from Sell at Citi... Cempra (CEMP) upgraded to Overweight from Equal Weight at Morgan Stanley... Edgewell Personal Care (EPC) upgraded to Neutral from Sell at Goldman... Eli Lilly (LLY) upgraded on improved growth outlook at BMO Capital... MiMedx (MDXG) upgraded to Strong Buy from Buy at Needham... NVIDIA (NVDA) upgraded to Buy from Hold at Canaccord... New York REIT (NYRT) upgraded to Buy from Hold at Evercore ISI... Oracle (ORCL) upgraded to Conviction Buy from Buy at Goldman... Perrigo (PRGO) upgraded to Buy from Neutral at UBS... Semtech (SMTC) upgraded to Buy from Neutral at B. Riley... Tullow Oil (TUWOY) upgraded to Buy from Neutral at UBS... Wabtec (WAB) upgraded to Outperform on valuatoin at Raymond James.
09:06 EDTUNHDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
08:06 EDTABCAmerisourceBergen upgraded to Equal Weight from Underweight at Morgan Stanley
Subscribe for More Information
07:04 EDTEXCExelon extends deadline for total exchange consideration for tendered notes
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use